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Background: During leisure activities young people are often exposed to excessive noise levels resulting in an
increase of noise-induced symptoms such as hearing loss, tinnitus and hyperacusis. Noise-induced tinnitus is often
perceived after loud music exposure and provides an important marker for overexposure as a temporary threshold
shift that is often not experienced by the individual itself. As oxidative stress plays an important role in the
pathogenesis of noise-induced hearing loss, the use of antioxidants to prevent hearing damage has recently
become the subject of research.
Methods: This study proposes a randomized, double-blind, placebo-controlled crossover trial to assess the effects
of a prophylactic combination of N-acetylcysteine (600 mg) and magnesium (200 mg) prior to leisure noise
exposure in young adults. The primary outcome measure is the tinnitus loudness scored by a visual analogue
scale (VAS). Secondary outcome measures are the differences in audiological measurements for the antioxidant
treatments compared to placebo intake. Audiological testing comprising of pure tone audiometry including
frequencies up to 16 kHz, distortion product otoacoustic emissions, transient-evoked otoacoustic emissions and
speech-in-noise testing will be performed prior to and within 7 hours after noise exposure. By use of a mixed effects
statistical model, the effects of antioxidants compared to placebo intake will be assessed.
Discussion: As adolescents and young adults often do not use hearing protection while being exposed to loud
music, the use of preventive antioxidant intake may provide a useful and harmless way to prevent noise-induced
hearing damage in this population. Furthermore, when exposed to hazardous noise levels the protection provided
by hearing protectors might not be sufficient to prevent hearing damage and antioxidants may provide additive
otoprotective effects. Previous research mainly focused on occupational noise exposure. The present study provides
a protocol to assess the usefulness of antioxidants during leisure noise activities.
Trial registration: The present protocol is registered at ClinicalTrials.gov: NCT01727492.
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Adolescents and young adults frequently expose them-
selves to hazardous noise levels during social events or
through personal listening devices. This has led to an in-
crease of noise-induced symptoms such as noise-induced
hearing loss (NIHL) and noise-induced tinnitus (NIT)
over the last few years [1,2]. Although 15% to 18% of the
young population already experiences permanent NIT and
the majority acknowledge the fact that loud music can
damage the hearing, the use of hearing protection remains
very low [3-5].
Oxidative stress plays a crucial role in the pathogenesis
of NIHL and NIT. During excessive noise exposure, the
outer hair cells endure metabolic depletion leading to
accumulation of reactive oxygen species (ROS) and re-
active nitrogen species (RNS) which may ultimately lead
to necrosis and apoptosis [6]. While necrosis is a passive
form of cell death, usually occurring after gross physical
or chemical insult, associated with cell swelling and
eventually causing cell rupture and loss of function,
apoptosis is an active way of cell death which also occurs
under normal metabolic circumstances [7]. However,
when apoptosis is ‘forced’ (for example as a consequence
of noise exposure) and by this initiated at the wrong
time, crucial healthy outer hair cells may die [7].
Under normal circumstances, the human cochlea con-
tains molecules including vitamins, glutathione, enzymes
and reactive transcription, which work together to form
a complex and sophisticated defense mechanism against
oxidative molecules [8]. In cases of excessive noise ex-
posure, the naturally occurring antioxidant systems may
not render sufficient detoxifying effects, leading to the
possible important role of antioxidant treatment after
acoustic trauma [9,10].
While antioxidant treatment for noise-induced hearing
damage has often been the subject of animal research
[11-17], well-performed human randomized controlled
trials remain scarce. Examining the literature, two anti-
oxidants have been mainly investigated as prophylactic
prevention in animal and also some human studies:
N-acetylcysteine (NAC) [18-21] and magnesium (Mg2+)
[22,23]. As oxidative stress triggers several cascades, it
has been proven that a combination of antioxidants may
provide better effects compared to a single antioxidant
[24]. Most human antioxidant studies have mainly inves-
tigated the effects during occupational noise exposure
[25]. Hence, the use of prophylactic antioxidants during
recreational noise is unclear. As the use of hearing
protection does not always render sufficient protection
while exposed to hazardous noise levels, an addition of
antioxidants may reduce noise-induced symptoms in
young people.
The present article proposes a protocol for a clinical
study consisting of a double-blind, randomized, placebo-controlled trial with a combination of NAC and Mg2+ as
prophylactic antioxidants in adolescents during leisure
noise exposure. The present report will follow the guide-
lines expressed by Consolidated Standards of Reporting
Trials (CONSORT).
Design
This study proposes a randomized, double-blind,
placebo-controlled crossover trial. Participants need to
spend at least 3 consecutive hours in an environment
where loud music is played (>95 dB(A)) after taking
either a combination of antioxidants (NAC and Mg2+) or
a placebo, 1 hour prior to noise exposure. Each partici-
pant needs to repeat this procedure four times (interval
between trials at least 4 days) and each participant will
receive twice the antioxidants as well as the placebo.
This study aims to investigate the combined effects of
NAC and Mg2+ by use of four repeated treatments on
the hearing of noise-exposed young adults.
Recruitment
We are recruiting students by advertisements sent by
email and distributing information sheets around the
University of Antwerp (Antwerp, Belgium). The aim is
to always investigate groups (at least two individuals) of
peers going out together and therefore attending the
clinic within the time range of 7 hours after noise expo-
sure. It is assumed that the pressure of peers also partici-
pating in the study will reduce the risk of drop-out. In
addition, at the stage of enrolment it will be determined
which occasions the subjects will attend and test mo-
ments will be scheduled. The aim is to plan all treat-
ments within the range of 3 months in order to reduce
the risk of drop-out.
Treatment protocol
Participants will receive an antioxidant combination of
NAC and Mg2+, or a placebo drug (sugar pill). The anti-
oxidant packets contain two pills of each 300 mg NAC
and 100 mg Mg2+. Both pills, providing a total dose of
600 mg NAC and 200 mg Mg2+, should be taken orally
1 hour before noise exposure with a large glass of water.
In 50%, the packets contain a placebo with an identical
appearance and weight as the antioxidants. All partici-
pants (as well as the researchers) will be blinded to the
order of antioxidants and placebo. The effects of NAC
and Mg2+ at the respective doses of 600 mg and 200 mg
will be analyzed as well as the effects of the combined
product, for which no significant adverse effects have
been reported in the past. Adverse events are defined as
symptoms occurring after the administration of antioxi-
dants or placebo that were not necessarily related to the
intervention. Participants will receive a telephone num-
ber to report adverse events during the study and will be
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Permitted and prohibited concomitant treatments
The use of alcohol and tobacco is limited to a maximum
of two alcohol consumptions and no to two cigarettes.
Other psychoactive drugs are strictly prohibited.
Inclusion criteria
The inclusion criteria are as follows:
 Age between 18 and 28 years old (males as well as
females).
 Experience of temporary tinnitus after leisure noise
exposure in the past scoring at least 5 or more on a
visual analogue scale (VAS) for loudness.
 Willing to attend an indoor/outdoor music event
with mean noise levels ≥95 dB(A) LAeq, 60 min for
at least 3 consecutive hours.
Exclusion criteria
The exclusion criteria are as follows:
 Middle ear pathologies such as otitis media and the
perforation of the tympanic membrane and history
of such pathologies.
 Known allergies for NAC or Mg2+.
 Adolescents using hearing protection.
 Recreational noise exposure within 4 days prior to a
study trial.
Randomization
The production of the antioxidant and placebo packets
as well as the randomization of the ABAB protocol will
be performed by an independent pharmacist. The
packets of antioxidants and placebos will be labeled with
a number corresponding with the numbers on the forms.
The randomization file will be put into a sealed envelope
and retained in a safe at the pharmacy. The randomi-
zation table will not be available for assessment by any-
one else involved in the study. At the end of the study
the envelope will be requested.
Sample size calculation and statistical analyses
A power calculation was performed in order to make an
estimation of the sample size needed to detect signi-
ficant differences in the VAS between the experimental
and control group by use of the software G-Power. A
two-sided paired t-test for mean differences was per-
formed in which an α-level of 0.05 and a nominal power
of 80% were used. Assuming a minimal difference of
clinical effect of 0.5 between the pre- and post-noise
measurements on the VAS, a non-parametric calculation
showed a requirement of 21 participants.All data in this trial will be assessed with SPSS Statistics
version 20.0 (SPSS, Chicago, IL, USA) and SAS version
9.1.3 (SAS, Cary, NC, USA). Because multiple correlated
measurements will be performed in the same participants,
a mixed effects model will be applied. This analysis is pre-
ferable over more traditional approaches such as repeated
measures analysis of variance (ANOVA) because of the
advantages to deal with missing values. The main analysis
will be fully specified before unmasking.Outcomes
The primary outcome measure will be the score on the
VAS for tinnitus loudness, which will be measured pre-
noise exposure (at the time of antioxidant intake) and 1
hour after noise exposure. The assumed expectation is a
drop of 50% of the tinnitus loudness in the antioxidant
group compared to the placebo group.
The secondary outcome measure is the evaluation of a
significant difference in test results of the audiological
testing (audiometry, otoacoustic emissions and speech-
in-noise tests) when comparing the placebo results to
the antioxidant trials.
A series of audiological tests (described in the follo-
wing paragraphs) will be performed prior to and within
7 hours after each noise exposure.Main outcome measure
Visual analogue scale (VAS) Tinnitus loudness will be
scored on a VAS from 0 to 10 (0, no tinnitus at all; 10,
extremely loud tinnitus, could not possibly be louder),
once at the time of antioxidant (or placebo) intake (1
hour prior to exposure) and once 1 hour after noise ex-
posure. At both occasions the VAS will be undertaken in
a quiet room.Secondary outcome measures
Pure tone audiometry Pure tone liminar audiometry
will be performed according to the current clinical stan-
dards (International Organization for Standardization
(ISO) 8253-1:2010) using a two-channel AC40 audiom-
eter (Interacoustics, Assens, Denmark) in a silent room.
Air conduction thresholds will be measured under head-
phones at 125 Hz, 250 Hz, 500 Hz, 1 kHz, 2 kHz, 3
kHz, 4 kHz, 6 kHz and 8 kHz. In addition, high fre-
quency air conduction thresholds will be performed in-
cluding 9 kHz, 10 kHz, 11,200 Hz, 12,500 Hz, 14 kHz
and 16 kHz. When air conduction thresholds between
250 Hz and 4 kHz exceed normality levels of 20 dB HL,
the bone conduction threshold will be measured on 250
Hz, 500 Hz, 1 kHz, 2 kHz, 3 kHz and 4 kHz in order to
make a distinction between conductive and sensori-
neural hearing loss.
Gilles et al. Trials 2014, 15:110 Page 4 of 5
http://www.trialsjournal.com/content/15/1/110Otoacoustic emissions Transient-evoked otoacoustic
emissions (TEOAEs) as well as distortion-product oto-
acoustic emissions (DPOAEs) will be performed. TEOAEs
are elicited with click sounds presented at an intensity
level of 80 dB SPL and recorded over a frequency range of
500 to 4,000 Hz. DPOAEs are elicited by use of a set of
two pure tone frequencies (f1 and f2) closely spaced and
presented simultaneously at a level of 55 dB SPL for f1
and 65 dB SPL for f2. The largest and most robust distor-
tion product is 2f1-f2 and can be detected in almost all
normal ears. The amplitude of 2f1-f2 is optimized by use
of the frequency ratio f2/f1 = 1.22. DPOAEs will be re-
corded in the frequency region from 1 kHz to 6 kHz.
Speech-in-noise testing Speech-in-noise testing will be
performed using the Leuven intelligibility sentence test
(LIST) [26] in an adaptive procedure with noise at a fixed
level of 65 dB SPL. Each list consists of ten sentences.
Both ears will be tested separately by use of headphones.
The procedure starts at a signal-to-noise ratio (SNR) of 0
dB meaning that speech and noise are presented with an
equal loudness (65 dB SPL). Subsequently, the intensity
level within a list of sentences varies in steps of 2 dB adap-
tively in a 1-down (when the keywords in the sentence are
correctly repeated), 1-up procedure to determine the 50%
correct identification point, which is called the speech
reception threshold (SRT), expressed in dB SNR. Three
conditions will be tested for both ears: sentences in
steady-state noise, sentences in amplitude-modulated
noise by a 10 Hz modulation and sentences in amplitude-
modulated noise by a 15 Hz modulation.
Controlling the noise levels In order to be able to re-
spect the inclusion criterion of the minimal noise levels
of 95 dB(A) LAeq, 60 min for 3 consecutive hours, all
participants will be equipped with portable decibel me-
ters (CEL350, Casella, Bedford, UK). The decibel meter
can be fixed onto a shirt or trousers but participants
must be aware that the microphone entrance should re-
main free from overhanging clothing.
Ethics
Written consent will be obtained from each participant.
This study protocol was approved by the ethical com-
mittee at Antwerp University Hospital in June 2012 with
protocol number 12/18/172.
Dissemination policy
According to the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines, the au-
thors declare that data that break the blind will not be
presented prior to the release of mainline results. The
breaking of the blind will occur at the end of the study. A
clinical article will be written on the primary (includingalso secondary) outcomes of the study and results will be
disseminated regardless of the magnitude or direction of
effect. The present trial is not industry-initiated. As such,
there are no publication restrictions imposed by sponsors.
In addition, a full study report, anonymized partici-
pant-level dataset and statistical code for generating the
results will be made publicly available no later than
3 years after the termination of the study for sharing
purposes.
Discussion
As adolescents and young adults often do not use hear-
ing protection while being exposed to loud music, the
use of preventive antioxidant intake may provide a use-
ful and harmless way to prevent noise-induced hearing
damage in this population. Furthermore, when exposed
to hazardous noise levels the protection provided by
hearing protectors might not be sufficient to prevent
hearing damage and antioxidants may provide additive
otoprotective effects. Previous research mainly focused
on occupational noise exposure. The present study will
assess the usefulness of antioxidants during leisure noise
activities.
The authors acknowledge the limitation of not including
blood samples in the present protocol in order to control
for naturally varying Mg2+ levels in the individual. How-
ever, the investigators considered that it was very likely
that the drop-out rate would be very high when partici-
pants needed to give a blood sample at every test moment,
which would be eight in total. It is also assumed that it is
the acute increase of NAC and Mg2+ prior to noise expo-
sure that provides the extra otoprotective effects and not
so much the naturally high or low levels.
To our knowledge, this study is the first to combine
NAC and Mg2+ as prophylactic antioxidants for noise-
induced tinnitus and noise-induced hearing damage in
young people performed in a randomized, placebo-
controlled trial. Furthermore, both participants and
investigators will be blinded for the sequence of anti-
oxidants and placebo. Thus, this would not influence on
one hand the participants in rating the tinnitus loudness
and on the other hand the investigators in performing
the audiological testing, limiting investigator bias as far
as possible.
Trial status
To date, half of the needed participants have been included
in the study. The procedure started in September 2012.
The study is anticipated to be completed in April 2014.
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